Pfizer To Provide US Additional 10M Courses Of COVID-19 Oral Therapy

by Vandana Singh, Benzinga Editor

January 4, 2022 12:43 PM | 1 min read |

The U.S. government has committed to purchasing an additional 10 million treatment courses of Pfizer Inc's PFE COVID-19 oral therapy, Paxlovid.
This commitment will supplement the 10 million treatment courses previously contracted by the U.S. Government, bringing the total amount of treatment courses to 20 million.
Collectively, approximately 10 million PAXLOVID treatment courses have been accelerated for delivery by the end of June, with the remaining 10 million to follow by the end of September.
The agency recently authorized the emergency use of Paxlovid for mild-to-moderate COVID-19 in adults and pediatric patients.
Price Action: PFE shares are down 2.71% at $55.12 during the market session on the last check Tuesday.

Posted In: Biotech Government News Health Care Contracts Movers Trading Ideas General Briefs COVID-19 Coronavirus

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.